- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04529941
Using Electrical Nerve Stimulation to Control Atrial Fibrillation (STALL-AF)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will have a 1:1 randomization to receive subcutaneous electrical nerve stimulation (ScNS) to observe if the stimulation can reduce atrial fibrillation burden in patients with symptomatic atrial fibrillation (AF). All subjects will undergo the implant of a neurostimulator lead. The experimental group will receive stimulation and the control group will not receive stimulation. All subjects will complete the same follow up visits to compare the 2 groups.
Primary Objective: To test the hypothesis that chronic subcutaneous nerve stimulation can reduce AF burden in patients with severe symptomatic AF unresponsive to conventional therapies
The secondary objective:
To test the hypotheses that the effect of ScNS on the following endpoints is different between the two randomization groups:
- Time-dependent reduction of AF burden
- Effects of ScNS on ventricular rate control during AF
- Reduction of SKNA
- Improvement of quality of life
The study will enroll patients with symptomatic atrial fibrillation unresponsive to conventional therapy defined by not responding to at least 1 antiarrhythmic drug. The study will enroll 30 patients, including 15 men and 15 women between the 18 and 75 years old. There will be no sex/gender/racial/ethnic based exclusion. Patients will be enrolled from the Cedars Sinai Medical Center.
The patients will undergo surgical implantation of an externalized lead under the skin on the chest wall. The wire is then connected to a neurostimulator. The experimental group (Group A) will receive ScNS (3.5mA) for two weeks. The sham group (Group B) will receive sham (0 mA) stimulation for two weeks. The AF burden will be assessed by a 7-day mobile cardiac telemetry device provided by Preventice. An additional mobile cardiac telemetry device, Bittium Faros, will also be worn at similar time points to monitor skin sympathetic nerve activity. An Apple watch will be used to collect additional information on the frequencies of AF between the Baseline Visit until the 3 Month Visit 7 Day Mobile Cardiac Telemetry is complete. After completion of the week 3 visit, the sham group (Group B) will be able to receive ScNS (3.5 mA) for two weeks. The AF burden will be assessed post-procedure by mobile cardiac telemetry by Preventice and Bittium Faros
Study duration: 36 Months
Subject duration: up to 5 months.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Peng-Sheng Chen, MD
- Phone Number: 310-423-6084
- Email: Chenp@cshs.org
Study Contact Backup
- Name: Tracey S Early, BS, MA
- Phone Number: 310.423.1231
- Email: tracey.early@cshs.org
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Recruiting
- CedarsSinaiMC
-
Contact:
- Anxhela Kote, BS
- Phone Number: 310-967-3854
- Email: anxhela.kote@cshs.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 to 75 years of age
Symptomatic Paroxysmal AF.
- Symptomatic paroxysmal AF is defined by AF with patient-reported perception of one or more of the following symptoms: palpitations, dizziness/presyncope, syncope, dyspnea, chest pain, malaise, and fatigue and activity intolerance.
- There is at least one ECG-documented AF episode.
- Unresponsive to conventional therapy is defined by not responding to at least 1 antiarrhythmic drug (class I, class III, or atrioventricular nodal blocker).
- The left atrial size <50 mm by transthoracic echocardiography documented by eligibility visit echocardiogram
- Documented atrial fibrillation as defined as atrial fibrillation >30 seconds in duration with an atrial fibrillation burden determined by a minimum of 7 days of continuous ePatch monitoring within 6 months before surgery.
Exclusion Criteria:
- Patients without AF episodes during monitoring period will be excluded from the study and count as screen failure
- Left ventricular ejection fraction <40%
- Heart failure with functional classes III or IV
- Recurrent vasovagal syncope
- Valvular AF (severe mitral regurgitation, mitral stenosis)
- Congenital heart diseases
- Wolff Parkinson-White Syndrome
- Stroke within the past 6 months
- Any history of myocardial infarction
- Malignancies with a life expectancy of < 1 year
- A history of ablation procedures to treat left atrial tachyarrhythmias or other serious comorbidity
- Any history of sustained ventricular tachycardia (VT) defined by (1) > 30 s in duration or (2) < 30 s in duration, but is associated with hemodynamic consequences such as hypotension and syncope.
- Patients with a vagal nerve stimulator
- Active thyrotoxicosis
- Sick sinus syndrome with symptomatic bradycardia
- Heart rate < 50 beats per minute in sinus rhythm on 12-lead ECG
- Systolic blood pressure < 90 mm Hg
- Any experimental medication concomitantly or within 4 weeks of participation in the study
- Subjects with cardiac implantable electronic device (CIED) such as pacemakers and implantable cardioverter-defibrillators (ICDs)
- Pre-existing neuromodulation devices, such as vagal nerve stimulators, spinal cord stimulators and sacral nerve stimulators
- People with a history of allergy to ECG electrodes, adhesive tape, or nylon
- Pregnant women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Group
Will receive stimulation ScNS at 3.5mA output
|
ScNS at 3.5mA output for 2 weeks
|
Sham Comparator: Control Group
Does not receive therapy
|
No device output for 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AF Burden
Time Frame: 2 weeks
|
Lower AF burden from Baseline in the active treatment group than the control group
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventricular Rate Control
Time Frame: 2 weeks
|
Improved ventricular rate control during AF
|
2 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Peng-Sheng Chen, MD, Cedars-Sinai Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00000581
- 7OT2OD028190-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
-
R-PharmFSBI "National Medical Research Center of Cardiology named after academician...CompletedAtrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationRussian Federation
Clinical Trials on Device Implant with Active Treatment
-
Click Therapeutics, Inc.WithdrawnSubstance Use Disorder | Drug Addiction | Tobacco Dependence | Drug Dependence | Nicotine AddictionUnited States
-
Elira, Inc.Recruiting
-
Temple UniversityPennsylvania Department of HealthActive, not recruitingRespiratory Viral Infection | Gastrointestinal InfectionUnited States
-
W.L.Gore & AssociatesCompletedThoracic DiseasesSweden, Netherlands, Spain, Germany, France, United Kingdom, Italy
-
Sección Hemodinamica y Cardiologia IntervencionistaUnknownCoronary Stenosis Treated With Implant of Bioresorbable DevicesSpain
-
Danyang Huichuang Medical Equipment Co., Ltd.First Affiliated Hospital of Chongqing Medical University; Rehabilitation Hospital...Enrolling by invitationMild to Moderate Alzheimer's DiseaseChina
-
Scientific Institute San RaffaeleRecruitingArrhythmia | Myocarditis | Cardiomyopathies | Ventricular Arrythmia | Immunosuppression | Genetic Predisposition | Inflammatory Cardiomyopathy | Catheter Ablation | AutoimmunityItaly
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Philips HealthcareCompleted